Shares of biotechnology company Equilllium (NASDAQ: EQ) have surged 16% premarket after the company announced it has received a Study May Proceed letter from the US Food and Drug Administration.
The letter means that the company can begin its Phase 3 clinical trial, named EQUINOX, evaluating itolizumab in hospitalised COVID-19 patients suffering from acute respiratory distress syndrome.
The San Diego based company said it plans to start enrolling patients during the fourth quarter with initial clinical data expected in the middle of 2021.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“The initiation of the EQUINOX Phase 3 trial represents an important milestone for Equillium and for COVID-19 patients worldwide. We look forward to partnering with Dr Douglas and our global sites to further evaluate itolizumab as a promising treatment for hospitalized COVID-19 patients,” commented Bruce Steel, Equillium’s CEO.
Back in July, Equillium’s partner, Biocon Limited revealed that a Phase 2 trial of itolizumab conducted in India showed “significantly reduced mortality over one month as compared to placebo in patients hospitalized with COVID-19.”
Equillium said the two companies are now working together to further development of the drug in coronavirus patients.
Today’s announcement has seen Equillium share jump to highs of $7.47. They are currently trading at $6.85, up 14.17% at the time of this publication.
PEOPLE WHO READ THIS ALSO VIEWED:
